RFK Jr.

Well, you know, my agency is the biggest agency in government. It's twice the size of the Pentagon. It represents about 20% of the U.S. economy worldwide. We have hundreds of institutes and sub-agencies. We try to be as careful as we can about what we cut and what we didn't. We made a couple of mistakes.

Well, you know, my agency is the biggest agency in government. It's twice the size of the Pentagon. It represents about 20% of the U.S. economy worldwide. We have hundreds of institutes and sub-agencies. We try to be as careful as we can about what we cut and what we didn't. We made a couple of mistakes.

Well, you know, my agency is the biggest agency in government. It's twice the size of the Pentagon. It represents about 20% of the U.S. economy worldwide. We have hundreds of institutes and sub-agencies. We try to be as careful as we can about what we cut and what we didn't. We made a couple of mistakes.

Senator, I understand. I understand that if you look at this from a distance, you'd say, why don't you just do this surgically and cut one person at a time? This agency has grown so big, so fast, and everybody who comes in says, I'm going to cut it down, and nobody's been able to do it. And there was an understanding that the longer that you wait, the more the inertia kicks in.

Senator, I understand. I understand that if you look at this from a distance, you'd say, why don't you just do this surgically and cut one person at a time? This agency has grown so big, so fast, and everybody who comes in says, I'm going to cut it down, and nobody's been able to do it. And there was an understanding that the longer that you wait, the more the inertia kicks in.

Senator, I understand. I understand that if you look at this from a distance, you'd say, why don't you just do this surgically and cut one person at a time? This agency has grown so big, so fast, and everybody who comes in says, I'm going to cut it down, and nobody's been able to do it. And there was an understanding that the longer that you wait, the more the inertia kicks in.

And we had to act quickly so that we can do something for the American people that is lasting. And we understood that there would be some mistakes made and that we would go back and reverse them when they were made. But it was more important to do decisive action quickly

And we had to act quickly so that we can do something for the American people that is lasting. And we understood that there would be some mistakes made and that we would go back and reverse them when they were made. But it was more important to do decisive action quickly

And we had to act quickly so that we can do something for the American people that is lasting. And we understood that there would be some mistakes made and that we would go back and reverse them when they were made. But it was more important to do decisive action quickly

That could eliminate the metastasizing of this agency to, you know, which was growing and growing, growing as our health declined.

That could eliminate the metastasizing of this agency to, you know, which was growing and growing, growing as our health declined.

That could eliminate the metastasizing of this agency to, you know, which was growing and growing, growing as our health declined.

That program will continue. There will be continuity in that.

That program will continue. There will be continuity in that.

That program will continue. There will be continuity in that.

I think the new data, first of all, it validates the CAS study, which is previously probably the most comprehensive data that we've seen on it. And it is and it's alarming. And clearly it indicates that at very least the label should be changed. I've asked Marty McCary, who's the director of FDA, to do a complete review and to report back. Good.

I think the new data, first of all, it validates the CAS study, which is previously probably the most comprehensive data that we've seen on it. And it is and it's alarming. And clearly it indicates that at very least the label should be changed. I've asked Marty McCary, who's the director of FDA, to do a complete review and to report back. Good.

I think the new data, first of all, it validates the CAS study, which is previously probably the most comprehensive data that we've seen on it. And it is and it's alarming. And clearly it indicates that at very least the label should be changed. I've asked Marty McCary, who's the director of FDA, to do a complete review and to report back. Good.

For measles? Probably for measles. You know, what I would say is my opinions about vaccines are irrelevant today. I have directed Jay Bhattacharya to the science so that everybody can make that decision. But I don't want to seem like I'm being evasive. But I don't think people should be taking advice, medical advice from me.

For measles? Probably for measles. You know, what I would say is my opinions about vaccines are irrelevant today. I have directed Jay Bhattacharya to the science so that everybody can make that decision. But I don't want to seem like I'm being evasive. But I don't think people should be taking advice, medical advice from me.